I'm Professor Charis Eng, the Hardis
chairperson of the Genomic Medicine
Institute and director at the
Center for Personalized Genetic
Healthcare at the Cleveland Clinic.
I shall be speaking to you about
the PTEN Hamartoma-tumour Syndrome
as a model for the practice
of clinical cancer genetics.
When we practice
clinical cancer genetics,
we ask ourselves when faced
with a patient with cancer,
is it heritable or is
it sporadic?, because this
has implications for the patient.
For example, which cancers will
this patient be at risk for?
At what ages do these risks arise?
What does one do for the patient?
In addition to the patient,
what are implications
for the patient's family?
Who amongst them is
at risk for cancer,
and what does one do for
each family member at risk?
Clinical clues suggesting heritable
cancer include young age of onset,
bilateral disease in paired organs,
multifocal tumors, association
with other tumor types-- for
example, breast and ovarian
cancer, colon and
Familial clustering of
cancers, but not always.